Death from all causes (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower death from all causes (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Recurrence of pulmonary emboli · patients with acute pulmonary embolism
Thrombolytic therapy may leads to lower recurrence of pulmonary emboli (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Major bleeding · patients with acute pulmonary embolism
Thrombolytic therapy probably leads to higher major haemorrhagic events (duration of compared with heparin: primary outcome measures (moderate certainty).
1 finding from 1 review
Minor haemorrhagic events (duration of · patients with acute pulmonary embolism
Thrombolytic therapy may leads to higher minor haemorrhagic events (duration of compared with heparin: primary outcome measures (low certainty).
1 finding from 1 review
Technical success · people with GSV incompetence
Endovenous laser ablation (EVLA) showed no clear difference in technical success (< 5 years) compared with radiofrequency ablation (RFA) (moderate certainty).
2 findings from 1 review
Long‐term recurrence (> 5 years) · people with GSV incompetence
It is very uncertain whether endovenous laser ablation (EVLA) changes long‐term recurrence (> 5 years) compared with ultrasound‐guided foam sclerotherapy (UGFS) (very low certainty).
1 finding from 1 review
Complications (up to 8 years) · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
QoL · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Technical success · people with GSV incompetence
Endovenous laser ablation (EVLA) may leads to higher technical success (< 5 years) compared with SFJ ligation and stripping (HL/S) (low certainty).
2 findings from 1 review
Recurrence · people with GSV incompetence
Endovenous laser ablation (EVLA) showed no clear difference in recurrence (< 5 years) compared with SFJ ligation and stripping (HL/S) (moderate certainty).
1 finding from 1 review
Long‐term recurrence (> 5 years) · people with GSV incompetence
Endovenous laser ablation (EVLA) showed no clear difference in long‐term recurrence (> 5 years) compared with SFJ ligation and stripping (HL/S) (moderate certainty).
1 finding from 1 review
Complications (up to 8 years) · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
QoL · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Technical success · people with GSV incompetence
Radiofrequency ablation (RFA) showed no clear difference in technical success (< 5 years) compared with mechanochemical ablation (MOCA) (low certainty).
2 findings from 1 review
Recurrence · people with GSV incompetence
Radiofrequency ablation (RFA) showed no clear difference in recurrence (< 5 years) compared with mechanochemical ablation (MOCA) (low certainty).
1 finding from 1 review
Long‐term recurrence (> 5 years) · people with GSV incompetence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complications (up to 1 year) · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
QoL · people with GSV incompetence
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Technical success · people with GSV incompetence
Radiofrequency ablation (RFA) showed no clear difference in technical success (< 5 years) compared with SFJ ligation and stripping (HL/S) (low certainty).
2 findings from 1 review
Recurrence · people with GSV incompetence
Radiofrequency ablation (RFA) showed no clear difference in recurrence (< 5 years) compared with SFJ ligation and stripping (HL/S) (moderate certainty).
1 finding from 1 review